Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Peptide Vaccine in Solid Tumors
NCT06614140Phase 2Completed
- Sponsor
- Seqker Biosciences
- Start
- Nov 2022
- Primary completion
- Aug 2025
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of personalized neoantigen peptide vaccine in solid tumor, sponsored by Seqker Biosciences. Primary endpoints: Safety of the Personalized Neoantigen Peptide Vaccine at 18 months and Immunogenicity of the Personalized Neoantigen Peptide Vaccine at 18 months. Started Nov 2022; status: completed.
02
Drugs
personalized neoantigen peptide vaccine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06614140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614140.